- A +

Board

 Michael Wyzga

Michael Wyzga
Chairman - Independant Director

Michael Wyzga
Chairman - Independant Director

 Michael Wyzga

Michael Wyzga has served as a member of our board of directors since October 2013.

Mr. Wyzga served as President and Chief Executive Officer and a member of the board of directors of Radius Health, Inc., a publicly traded biopharmaceutical company, from December 2011 until November 2013.

Prior to that, Mr. Wyzga served in various senior management positions at Genzyme Corporation, a publicly traded global biotechnology company. Mr. Wyzga joined Genzyme in February 1998 and most recently served as Executive Vice President, Finance from May 2003 until November 2011 and as chief financial officer from July 1999 until November 2011.

Since February 2014, Mr. Wyzga has served as a member of the board of directors of Akebia Therapeutics, Inc., a publicly traded biopharmaceutical company, where he is also a member of the compensation committee and chair of the audit committee.

Since February 2015, Mr. Wyzga has also served as a member of the board of directors of Exact Sciences Corporation, a publicly traded medical technology company, where he is also a member of the audit and compensation committees.

Mr. Wyzga also previously served as a member of the board of directors of Idenix Pharmaceuticals, Inc., a publicly traded biotechnology company that was acquired by Merck in August 2014, where he also served as the chair of the audit committee and a member of the compensation committee, and Altus Pharmaceuticals, Inc., a publicly traded biopharmaceutical company that ceased operations in November 2009, and as a member of the Supervisory Board of Prosensa Holding B.V., a publicly traded biopharmaceutical company, from June 2014 until the Prosensa acquisition by BioMarin Falcon B.V. in December 2014.

He received an M.B.A. from Providence College and a B.S. from Suffolk University. 

Bernard Gilly, PhD

Bernard Gilly, PhD
Co-Founder, CEO - Director

Bernard Gilly, PhD
Co-Founder, CEO - Director

Bernard Gilly, PhD

Bernard Gilly is one of our founders, and has served as our Chief Executive Officer since GenSight's creation in 2012. 

Bernard has over twenty years of experience in the financial and pharmaceutical sectors. He co-founded several high potential start-ups, developing disruptive technologies in the biotech and medtech fields.

He is currently non-executive Chairman of Pixium Vision (since 2011), EyeTechCare (2012), Gecko Biomedical (2013) and Chronocam (2015). From 2005 to 2009, he founded and was Chairman and Chief Executive Officer of Fovea Pharmaceuticals, a privately owned biotech company, which was acquired by Sanofi in 2009. After the acquisition, he became Senior Vice-President of the Ophthalmology Division of Sanofi until 2012.

Prior to Fovea, Dr. Gilly was a partner at Sofinnova Partners from 2000 to 2005. From 1992 to 2000, he was Chief Executive Officer of Transgene. At that time, he took the company public on the NASDAQ and the Nouveau Marché in France, raising over $120M in 1998. 

Prior to that, he was VP of R&D at Pasteur Mérieux Connaught (now Sanofi Pasteur).

Dr. Gilly received an engineering degree from Ecole Nationale d’Agronomie and a Ph.D. from Université de Rennes.

Genghis Lloyd-Harris, MD, PhD

Genghis Lloyd-Harris, MD, PhD
Director

Genghis Lloyd-Harris, MD, PhD
Director

Genghis Lloyd-Harris, MD, PhD

Genghis Lloyd-Harris, M.D., Ph.D., is Partner at Abingworth.

Prior to joining Abingworth in 2004, Dr. Lloyd-Harris was Managing Director in the European equity research group at Credit Suisse First Boston (CSFB) where he was responsible for coverage of the European biotechnology industry and was ranked first for Pan-European Biotechnology in the Institutional Investor surveys each year from 2001 to 2003.

Before joining equity research at CSFB, he worked for CSFB’s health care group in the investment banking division in New York.

Dr. Lloyd-Harris was previously a pediatrician in Melbourne, Australia. Dr.

Lloyd-Harris holds a medical degree from the University of Liverpool, UK, a Ph.D. in clinical pharmacology from the University of Melbourne, Australia, and an MBA from Harvard Business School.

Dr. Lloyd-Harris currently serves on the board of Avillion LLP, Wilson Therapeutics AB and Abingworth LLP, and has previously served on the board of several companies, including Solexa Inc., Novexel S.A., HBI Ltd., Syntaxin Ltd., In Pharmatica Ltd. and Synosia AG. 

Guido Magni, MD, PhD

Guido Magni, MD, PhD
Director

Guido Magni, MD, PhD
Director

Guido Magni, MD, PhD

Guido Magni, M.D., Ph.D., is a Partner with Versant Ventures, based in Basel, Switzerland.

Dr. Magni previously served as a Managing Director of EuroVentures, a Versant incubator, where he was involved with several biotech investments including Synosia Therapeutics AG, which was sold to Biotie Therapeutics AG, or Biotie, Flexion Therapeutics AG and Okairos AG, which was sold to GSK.

Dr. Magni was previously Global Head of Medical Sciences in Roche, in the Global Drug Development department. During his twelve years in this position, Dr. Magni oversaw the development and the registration of a large number of new chemical and biological entities including Pegasys, Mabthera, Xeloda, Herceptin, Tamiflu and Tarceva.

Dr. Magni currently serves on the board of Biotie, Piqur Therapeutics AG and AM Pharma B.V..

Dr. Magni has an M.D. degree from the University of Padua and a Ph.D. in neuropharmacology.

Earl M. Collier, J.D.

Earl M. Collier, J.D.
Independant Director

Earl M. Collier, J.D.
Independant Director

Earl M. Collier, J.D.

Earl M. Collier, J.D., served from 2010 to 2014 as the Chief Executive Officer of 480 Biomedical, a medical device company developing products used in the treatment of peripheral artery disease, and the executive chairman of Arsenal Medical, Inc., a medical device company. Mr. Collier was formerly Executive Vice President at Genzyme Corporation, a biotechnology company acquired by Sanofi for $20.1 billion in 2011. During his tenure at Genzyme, Mr. Collier was responsible for building the biosurgery business and overseeing the company’s efforts in oncology, multiple sclerosis and other immune disorders. He led some of Genzyme’s significant acquisitions and the formation of MG Biotherapeutics, Genzyme’s joint venture with Medtronic Inc., which focused on cardiac cell therapy.  Mr. Collier also served as President of Vitas Healthcare, a hospice provider, as a partner at the Washington, DC-based law firm of Hogan and Hartson and as Deputy Administrator of the Health Care Finance Administration (now CMS) in the U.S. Department of Health & Human Services. He is Chairman of the Board of Trustees of Newton-Wellesley Hospital, serves on the board of Partners HealthCare System and as Chair of the Innovation Advisory Board of Partners HealthCare. From 2006 to 2009, Mr. Collier served as a director of publicly-traded Decode Genetics Inc. (DGI Resolution, Inc.), a biopharmaceutical company, and he currently serves on the board of directors of Capricor Therapeutics, Inc., a clinical stage biotechnology company, Tesaro, Inc., a publicly-traded biopharmaceutical company and Transmedics, a private medical device company. Mr. Collier earned a Bachelor of Arts degree at Yale University and received a law degree from the University of Virginia Law School.  

Maïlys Ferrère

Maïlys Ferrère
Director

Maïlys Ferrère
Director

Maïlys Ferrère

Maïlys Ferrère is Director of the Large Venture Investment Pole within the Innovation Division of Bpifrance. Large Venture’s mission is to provide long term capital to innovative French companies in areas with very strong growth with the goal of creating world leaders. The portfolio currently includes thirty companies in life sciences, digital and environmental technologies.

Prior to this position, Maïlys was an Investment Director at the Strategic Investment Fund between 2009 and 2012. She previously had a career in banking, specialized in equity capital markets in various financial institutions.

Maïlys Ferrère is a member of the Boards of Directors or Supervisory Boards of the following companies: DBV, Valneva SE, Pixium Vision and Euronext Paris.

Peter Goodfellow

Peter Goodfellow
Independant Director

Peter Goodfellow
Independant Director

Peter Goodfellow

Peter Goodfellow, Ph.D., is a science advisor and consultant for Abingworth LLP, or Abingworth, Sanofi and the Bill and Melinda Gates Foundation.

Dr. Goodfellow was previously the Balfour Professor of Genetics at Cambridge University before working for SmithKline Beecham (later GSK) as head of research. He has founded two biotechnology companies and has sat on the Boards of Prosensa Holdings N.V., deCode and several medical charities.

Dr. Goodfellow holds doctorates from Oxford and Bristol Universities.

Jose-Alain Sahel, MD, PhD

Jose-Alain Sahel, MD, PhD
Observer

Jose-Alain Sahel, MD, PhD
Observer

Jose-Alain Sahel, MD, PhD

Jose-Alain Sahel is Professor at Université Pierre et Marie Curie, and Director of Institut de la Vision and Chairman of the Department of Ophthalmology at the Quinze-Vingts National Eye Hospital and at the Rothschild Ophthalmology Foundation in Paris, France. He is also Professor at the Institute of Ophthalmology at the University College in London.

He has been conducting pioneering research into the understanding of the pathological mechanisms involved in retinal cell degeneration.

Prof. Sahel recently received awards from the US Foundation Fighting Blindness and the French “Académie des Sciences”, for his work on retinitis pigmentosa.

Thibaut Roulon, PhD

Thibaut Roulon, PhD
Observer

Thibaut Roulon, PhD
Observer

Thibaut Roulon, PhD

Thibaut started his career as a scientist in a US biotech company developing cancer immunotherapeutics. In 2005 he joined Bioam Gestion, a venture capital firm investing in life science companies.

In 2010, Bioam merged with Bpifrance Investissement (formerly known as CDC Entreprises), a leading French investment firm investing in SMEs and mid-Tier companies. He is in charge of managing investments in life sciences companies (Seed, Venture, IPO, PIPE).

Thibaut is a graduate of the Ecole Centrale de Paris and holds a PhD from the Pierre & Marie Curie University.